Skip to main
MESO
MESO logo

Mesoblast (MESO) Stock Forecast & Price Target

Mesoblast (MESO) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 25%
Buy 25%
Hold 38%
Sell 0%
Strong Sell 13%

Bulls say

Mesoblast Ltd has demonstrated significant growth potential, with projected revenues from Ryoncil expected to increase from $24 million in 2025 to $368 million by 2032. The company’s enhanced enterprise value is now estimated at $3.16 billion, reflecting a substantial increase from previous valuations, driven by the potential of its therapies and international partnerships. Additionally, the promising clinical outcomes of Ryoncil, showing improved survival rates compared to available therapies, and the increase in valuation for multiple product candidates further support a positive outlook for the company's financial performance.

Bears say

Mesoblast Ltd faces significant challenges that contribute to a negative outlook for its stock. The company's reliance on JCR for TEMCELL sales may result in lower-than-expected royalty revenues, compounded by clinical trial risks that could negatively impact product approval timelines and success rates. Additionally, the potential inadequacies in safety and efficacy profiles, as highlighted by recent adverse event data and regulatory hurdles, further diminish confidence in the company’s ability to achieve its commercialization goals.

Mesoblast (MESO) has been analyzed by 8 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 0% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mesoblast and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mesoblast (MESO) Forecast

Analysts have given Mesoblast (MESO) a Hold based on their latest research and market trends.

According to 8 analysts, Mesoblast (MESO) has a Hold consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mesoblast (MESO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.